Introduction: The 'Guidelines for a healthy canteen in workplaces' (guidelines) was published in 2013 by the Ministry of Health to improve food choices & healthy eating of working community.

Objectives: To determine the extent of implementation of guidelines in canteens at medical institutions in Anuradhapura District.

Methods: A descriptive cross-sectional study was conducted on random working days in canteens providing all three main meals in medical institutions in Anuradhapura District in August and September 2018. Data were collected by observing the canteen and interviewing the canteen owners according to guidelines. Scoring was done according to a scoring system to obtain a percentage.

Results: Ten canteens were included in the study. The median number of customers per canteen was 200 (IQR 100-625). The highest and lowest scores by canteens for overall implementation were 41.8% and 14.1%, while the mean among all canteens was 29.2%. Average percentages for healthy carbohydrate, fruit, snacks, and oil options were 15.2%, 20.0%, 8.8%, and 28.2% respectively. Availability of healthy dairy and use of standard coconut oil was 0.0%. Safe drinking water and hand-washing with soap were available only in 6 and 4 canteens respectively. Implementation of food safety measures was 32.5%. None of the canteens had any posters/ guides regarding healthy eating and none of the owners were aware of the guidelines.

Conclusions: The level of implementation of the canteen guidelines was highly unsatisfactory among the canteens in medical institutions in Anuradhapura District.

Download full-text PDF

Source
http://dx.doi.org/10.4038/cmj.v66i3.9489DOI Listing

Publication Analysis

Top Keywords

medical institutions
16
institutions anuradhapura
16
canteens medical
12
anuradhapura district
12
canteens
9
canteen guidelines
8
healthy eating
8
canteens implementation
8
guidelines
5
implementation
5

Similar Publications

Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.

View Article and Find Full Text PDF

Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.

Background: The initiation of amyloid plaque deposition signifies a crucial stage in Alzheimer's disease (AD) progression, which often coincides with the disruption of neural circuits and cognitive decline. While the role of excitatory-inhibitory balance is increasingly recognized in AD pathophysiology, targeted therapies to modulate this balance remain underexplored. This study investigates the effect of perampanel, a selective non-competitive AMPA receptor antagonist, in modulating neurophysiological changes in hAPP-J20 transgenic Alzheimer's mice.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

ADEL Institute of Science & Technology (AIST), ADEL, Inc., Seoul, Korea, Republic of (South).

Background: The Apolipoprotein E4 isoform (ApoE4), encoded by the APOE gene, stands out as the most influential genetic factor in late-onset Alzheimer's disease (LOAD). The ApoE4 isoform contributes to metabolic and neuropathological abnormalities during brain aging, with a strong correlation observed in APOE4-positive Alzheimer's disease cases between phosphorylated tau burden and amyloid deposition. Despite compelling evidence of APOE-mediated neuroinflammation influencing the progression of tau-mediated neurodegeneration, the molecular mechanisms underlying these phenomena remain largely unknown.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!